Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling

Abstract excerpt

BACKGROUND: Thirty to forty percent of patients with Diffuse Large B-cell Lymphoma (DLBCL) have an adverse clinical evolution. The increased understanding of DLBCL biology has shed light on the clinical evolution of this pathology, leading to the discovery of prognostic factors based on gene expression data, genomic rearrangements and mutational subgroups. Nevertheless, additional efforts are needed in order to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous lymphoproliferative disorders research
• Share to Lymphoma Diagnosis and Treatment
• Share to T-cell and Retrovirus Studies